Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

FDA approves STADA's Lucamzi (ranibizumab-blrz) biosimilar for neovascular wet age-related macular degeneration following Ph3 success
Protein therapy, ophthalmology, biosimilar, monoclonal antibody, anti-VEGF, wet age-related macular degeneration - Read more

BioMarin licenses Fabry ERT candidate from GC Biopharma, Hanmi Pharm for $70M upfront, up to $475M total
Licensing deal, rare disease, enzyme replacement therapy, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Ascletis' ASC30 (small-molecule glucagon-like peptide-1 receptor agonist) meets Ph2 endpoints in type 2 diabetes trial
Small molecule, metabolic, GLP-1 receptor agonist, type 2 diabetes, obesity - Read more

Hansa Biopharma's Idefirix (imlifidase) shows 90% graft failure-free survival in post-authorization study for highly sensitized kidney transplant patients
Protein therapy, transplantation, monoclonal antibody, kidney transplant, highly sensitized patients, imlifidase - Read more

OSE Immunotherapeutics' Tedopi (OSE2101) meets primary endpoint in Ph2 trial for metastatic non-small cell lung cancer
Vaccine, cancer, cancer vaccine, non-small cell lung cancer, combination therapy, anti-PD1 - Read more

Flagship Pioneering merges Etiome, Cellarity, and Empress Therapeutics into new AI drug discovery venture Etcelera
Small molecule, hematological, AI drug discovery, strategic - Read more

Merck & Co. beats Q3 estimates with Keytruda, Gardasil, and Winrevair all outperforming forecasts
Monoclonal antibody, oncology, revenue impact, financial - Read more

Eli Lilly's 2026 guidance jumps $10B as GLP-1 sales, Medicare Bridge program exceed expectations
GLP-1, obesity, financial, revenue impact - Read more

Dren Bio raises $350M private financing to advance blood cancer drug dibotatug to market
Hematologic malignancies, monoclonal antibody, autoimmune, oncology, platform technology, clinical-stage - Read more

Formation Bio unveils $600M Drug Development Accelerator Fund to acquire 10-15 drug programs
AI-driven, drug development, clinical-stage, platform-enabled - Read more

BioGeometry closes Series A rounds totaling $100M+, advancing AI-native biological world models
AI/ML platform, drug discovery, platform technology, preclinical - Read more

Lonza expands Swiss ADC manufacturing hub in Visp, adding mid-scale bioconjugation suites for 2028 launch
Antibody-drug conjugate, oncology, operational, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Geron's Rytelo (imetelstat) Ph3 trial fails in JAK inhibitor-pretreated myelofibrosis, missing overall survival endpoint
Small molecule, blood cancer, telomerase inhibitor, myelofibrosis, myelodysplastic syndromes, JAK inhibitor - Read more

Ono Pharma drops ONO-1110 depression, social anxiety disorder programs after Ph2 failures, pursues pain indications
Small molecule, neurological, endocannabinoid modulator, depression, pain, social anxiety disorder - Read more

Bristol Myers Squibb's Cobenfy misses Q3 sales estimates by $11M amid slow schizophrenia launch
Small molecule, neurological, competitive, revenue impact - Read more

HHS allows compounders to make six unapproved peptides, bypassing FDA safety concerns
Peptide compounding, multi-disease, regulatory, competitive - Read more

Bristol Myers Squibb terminates $80M Prothena-licensed neurodegeneration program BMS-986495 after phase 1
Licensing deal, neurological, antibody, milestone payments - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here